BMS Archive

Fungi · Scientific monograph

Pleurotus ostreatus

Oyster Mushroom

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Cardiovascular System, Glucose & Metabolic Research, Immunological Research

Research overview

Historical use

Consumed as food across Europe and Asia for centuries. Less prominent in traditional medicine than Asian medicinal fungi, but used in Eastern European folk medicine for general health. One of the most widely cultivated mushrooms globally, appreciated for culinary and nutritional value. References to medicinal use in Slavic folk medicine for liver and cardiovascular conditions.

Modern research context

Among edible fungi, oyster mushrooms have the most clinical evidence for lipid-lowering effects; a review of clinical and preclinical studies confirms cardiometabolic benefits [1][2]. Consumption of P. ostreatus extract has been associated with improvements in blood parameters and cytokine profiles in clinical studies [3]. Lovastatin (mevinolin) content — a genuine statin naturally occurring in the fruiting body — is the likely cholesterol-lowering mechanism [2]. Immunomodulatory properties and anti-cancer activity are documented in preclinical and review literature [4][5]. Pleuran (beta-1,3/1,6-glucan) from P. ostreatus is commercially used as an immunomodulatory supplement [4].

Adverse effects

Generally very well tolerated. Rare contact dermatitis (occupational). Rare asthma with spore inhalation. Possible GI intolerance with very large consumption.

Contraindications

Statins (atorvastatin, simvastatin) — additive lipid-lowering effect and potential for myopathy due to lovastatin content. Caution in patients with myopathy. Immunosuppressants — pharmacodynamic antagonism (pleuran).

Clinical and phytochemical data

Used part

Fruiting body

Primary active compounds

  • Pleuran (beta-1,3/1,6-glucan)

  • Lovastatin (mevinolin) — 2.8% dry weight in some varieties

  • Polysaccharides

  • Phenolic compounds (gallic acid, p-coumaric acid)

  • Ergothioneine

  • GABA

Mechanism of action

Lovastatin competitively inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptor expression. Beta-glucans activate Dectin-1, promoting Th1 immune response. ACE-inhibitory peptides reduce angiotensin II formation, producing antihypertensive effects. Ergothioneine acts as antioxidant via Nrf2/HO-1 upregulation.

Pharmacokinetics

Absorption

Absorption is compound-dependent. Lovastatin, present at up to 2.8% dry weight in some Pleurotus ostreatus varieties, has very low oral bioavailability in humans (~5%) due to extensive first-pass metabolism at both intestinal and hepatic levels; this is well-characterised in human clinical pharmacokinetic studies [1]. Ergothioneine, also present in oyster mushroom, is avidly absorbed after oral administration in healthy humans with significant plasma and whole blood elevations [2]. No human bioavailability data exist for pleuran (beta-glucan) or other polysaccharide fractions — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Lovastatin absorbed in prodrug (lactone) form; hydrolysed to active hydroxy acid in gut/liver; bioavailability ~5% due to first-pass effect. Pleuran: limited systemic absorption; active at mucosal/GALT level.

Distribution

Lovastatin is extensively distributed to hepatic tissue (target organ) following absorption; high plasma protein binding (>95%) limits free drug concentrations [1]. Ergothioneine distributes into whole blood and erythrocytes via the OCTN1 transporter after oral dosing in humans [2]. Distribution of pleuran and other polysaccharides has not been characterised in humans — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Lovastatin undergoes extensive hepatic first-pass metabolism; the active β-hydroxy acid metabolite distributes systemically with high hepatic uptake (target organ) and ~95% plasma protein binding. Ergothioneine concentrates in erythrocytes via OCTN1 transporter. Polysaccharide fractions confined to GI/GALT. Volume of distribution of lovastatin ~0.5 L/kg.

Metabolism

Lovastatin is a prodrug (inactive lactone) hydrolysed to the active hydroxy acid form; it undergoes extensive CYP3A4-mediated first-pass metabolism at intestinal and hepatic levels, accounting for its low oral bioavailability [1]. Ergothioneine is partially biotransformed in vivo to hercynine and S-methyl-ergothioneine, as measured in human whole blood after oral dosing [2]. No human metabolic data exist for pleuran or other polysaccharide fractions — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Lovastatin extensively metabolised by CYP3A4 to active and inactive metabolites. Pleuran fermented by gut microbiota.

Excretion

Lovastatin and its metabolites are excreted primarily via bile into faeces (~83%); renal excretion accounts for approximately 10% [1]. Ergothioneine is largely retained in the body; urinary excretion is less than 4% of the administered oral dose in humans [2]. Renal or biliary excretion of pleuran has not been characterised in humans — No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Lovastatin: primarily biliary/fecal (83%); minor renal (10%). Pleuran: fecal.

Safety and interactions

Drug interactions

Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.

Toxicity

Whole mushroom: LD50 not established; dietary consumption is safe. Concentrated lovastatin-rich extracts carry statin-class adverse effects (myopathy, elevated liver enzymes) at pharmacological doses.

Special precautions

Pregnancy

Dietary consumption of culinary amounts carries no documented risk based on long traditional food use; no teratogenicity has been demonstrated at food-level doses. However, Lovastatin (a secondary metabolite present at low levels in the fruiting body) is contraindicated during pregnancy (Category X statin classification — teratogenic in animal models). High-dose concentrated extracts should be avoided due to insufficient clinical safety data during pregnancy.

Lactation

Lovastatin excreted in breast milk. Concentrated lovastatin-containing preparations should be avoided during breastfeeding.

Hepatic impairment

Lovastatin is contraindicated in active liver disease. Monitoring of liver enzymes with regular high-dose consumption is prudent.

Renal impairment

Lovastatin primarily excreted biliary; mild renal impairment generally does not require dose adjustment. Severe renal impairment — use with caution.

Sources and references

  1. [1] - Dicks L., "Effect of the Intake of Oyster Mushrooms (Pleurotus ostreatus) on Cardiometabolic Parameters-A Systematic Review.", Nutrients, 2020, PMID: 32316680
  2. [2] - Araújo PL., "Pleurotus Mushrooms in Nutrition and Health: Clinical and Preclinical Insights for Nutraceutical Applications.", Compr Rev Food Sci Food Saf, 2025, PMID: 40899490
  3. [3] - Dündar A., "Effect of Pleurotus ostreatus Water Extract Consumption on Blood Parameters and Cytokine Values in Healthy Volunteers.", J Am Nutr Assoc, 2024, PMID: 38935369
  4. [4] - Motta F., "Mushrooms and immunity.", J Autoimmun, 2021, PMID: 33276307
  5. [5] - Gariboldi MB., "Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer.", Int J Mol Sci, 2023, PMID: 37373268

Additional source links

Continue browsing